InsidersTradesSigma
Repare Therapeutics Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Repare Therapeutics Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are quoted on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Repare Therapeutics Inc. has recorded 151 insider filings. The latest transaction was filed on 29 April 2025 (Attribution). Among the most active insiders: GADICKE ANSBERT. All data is free.
151
Insider Decl.
0
Thresholds
€28m
9 ops.
Buy Volume
€56m
105 ops.
Sell Volume
42Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 29 April 2025
Declarations151 total
4,100 shares0Common SharesSEC:0001415889-25-011515:0
3,596 shares@ US$1.141.2% of flowCommon SharesSEC:0001415889-25-008108:0
6,884 shares@ US$1.1450.0% of flowCommon SharesSEC:0001415889-25-008106:0
21,179 shares@ US$1.142.5% of flowCommon SharesSEC:0001415889-25-008105:0
5,611 shares@ US$1.140.3% of flowCommon SharesSEC:0001415889-25-008107:0
40,000 shares0Common SharesSEC:0001415889-25-007239:0
14,000 shares0Common SharesSEC:0001415889-25-007238:0
14,000 shares0Common SharesSEC:0001415889-25-007237:0
450 shares@ US$4.640.1% of flowCommon SharesSEC:0001415889-24-009625:0
500 shares@ US$4.640.7% of flowCommon SharesSEC:0001415889-24-009623:0
2,650 shares@ US$4.621.3% of flowCommon SharesSEC:0001415889-24-009629:0
825 shares@ US$4.6224.5% of flowCommon SharesSEC:0001415889-24-009627:0
2,650 shares@ US$4.791.3% of flowCommon SharesSEC:0001415889-24-009249:0
450 shares@ US$4.780.1% of flowCommon SharesSEC:0001415889-24-009253:0
500 shares@ US$4.780.7% of flowCommon SharesSEC:0001415889-24-009251:0
825 shares@ US$4.7925.4% of flowCommon SharesSEC:0001415889-24-009255:0
14,000 shares0Common SharesSEC:0001415889-24-006590:0
14,000 shares0Common SharesSEC:0001415889-24-006466:0
40,000 shares0Common SharesSEC:0001415889-24-006464:0
14,000 shares0Common SharesSEC:0001415889-24-006462:0
20,190 shares@ US$2.06212.2% of flowCommon SharesSEC:0001209191-23-058272:0
493,337 shares@ US$4.99998.3% of flowCommon Shares, no par valueSEC:0000921895-23-002669:0
Ideal exit: 11 Aug 2024 (T+270)
218,979 shares@ US$3.602.7% of flowCommon Shares, no par valueSEC:0000921895-23-002458:0
Ideal exit: 29 Jul 2024 (T+270)
6,404 shares@ US$12.034.1% of flowCommon SharesSEC:0001209191-23-035858:0
1,200 shares@ US$12.040.8% of flowCommon SharesSEC:0001209191-23-035135:0
25 of 151 declarations
About Repare Therapeutics Inc.
Repare Therapeutics Inc. (ticker: RPTX) is a clinical-stage biotechnology company listed on the NASDAQ market in the United States (United States), focused on precision oncology. The company’s scientific core is a synthetic lethality platform, designed to identify genetic vulnerabilities in cancer cells and translate those insights into targeted therapies. Repare was founded in 2016 and incorporated under the Canada Business Corporations Act on September 6, 2016. Operationally, it is anchored in Montreal, Quebec, with a significant presence in Cambridge, Massachusetts, and it also maintains Repare Therapeutics USA Inc., its U.S. subsidiary. This cross-border setup gives the company access to both Canadian scientific talent and the large U.S. capital and clinical ecosystem. Repare’s business model is centered on proprietary drug discovery and development, supported by its SNIPRx® platform and a genomics-driven approach to patient selection. Rather than operating as a commercial drug company, Repare is still in the high-risk, high-reward development phase, where the value proposition depends primarily on clinical execution, regulatory progress, and strategic partnering. Its pipeline has historically included both partnered and wholly owned assets, but management has increasingly focused the portfolio on a smaller number of programs with the highest near- to medium-term potential. Key product candidates include lunresertib (RP-6306), a PKMYT1 inhibitor; camonsertib (RP-3500), an ATR inhibitor; RP-1664, a PLK4 inhibitor; and RP-3467, a Polθ ATPase inhibitor. These programs target DNA damage response and cell-cycle biology, areas that remain highly active in oncology research because they may create differentiated opportunities in genomically defined tumors. Repare’s competitive position is therefore that of a science-led precision oncology platform company, competing against other biotech firms developing DNA repair and replication stress therapies. Its edge lies in target selection, translational data, and the ability to generate clinically meaningful signals in biomarker-selected populations. Recent developments have been strategically important. In 2024 and 2025, the company undertook portfolio reprioritization and cost reductions, concentrating resources on RP-1664 and RP-3467 while seeking partnerships for lunresertib and camonsertib. In parallel, Repare reported ongoing clinical activity and preclinical work across its pipeline. Most notably, the company later announced a definitive agreement to be acquired by XenoTherapeutics, Inc., subject to customary approvals, and separately disclosed an asset sale of RP-3467 to Gilead Sciences for up to $30 million in total consideration. For investors, RPTX remains a NASDAQ-listed United States biotech story defined less by current revenues than by clinical milestones, portfolio monetization, and transaction-driven optionality.
